Peptide Fragments

Peptide Fragments
Accession Number

Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.

DrugDrug Description
CaplacizumabA von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP).
Certolizumab pegolA tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
DulaglutideA GLP-1 agonist used to manage type 2 diabetes mellitus.
LuspaterceptAn erythroid maturation agent used to treat anemia secondary to beta thalassemia, myelodysplastic syndromes, and neoplasms.
EnfuvirtideAn HIV-1 gp41 fusion inhibitor used in patients experiencing HIV-1 replication who are already being treated with other anti-retrovirals.
Eftrenonacog alfaA recombinant Factor IX used to treat and prevent bleeding in hemophilia B.
DalanterceptDalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).
EflapegrastimA form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy.
IpafriceptIpafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors).
AbciximabA monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.
PexelizumabFor the treatment of inflammation during cardiac surgery.
PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
LampalizumabLampalizumab has been used in trials studying the treatment of Geographic Atrophy.
GancotamabGancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).
VobarilizumabVobarilizumab is under investigation in clinical trial NCT02101073 (ALX-0061 Phase I Bioavailability Study in Healthy Volunteers).
Dapirolizumab pegolDapirolizumab pegol is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).
GontivimabGontivimab is under investigation in clinical trial NCT03468829 (Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection).
Evorpaceptevorpacept is under investigation in clinical trial NCT04755244 (A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)).
BI-836858Not Annotated
EDI-200EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.
Peptide YY (1-36)Not Available
Drugs & Drug Targets
Caplacizumabvon Willebrand factortarget
Certolizumab pegolTumor necrosis factortarget
Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
DulaglutideGlucagon-like peptide 1 receptortarget
EnfuvirtideEnvelope glycoproteintarget
EnfuvirtideCytochrome P450 2C19enzyme
EnfuvirtideCytochrome P450 2E1enzyme
EflapegrastimGranulocyte colony-stimulating factor receptortarget
AbciximabIntegrin beta-3target
AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
AbciximabIntegrin alpha-IIbtarget
PRO-542Free fatty acid receptor 4target